BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models (original) (raw)
Bedano PM, Hanna NH . (2006). Salvage therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol1: 582–587. ArticlePubMed Google Scholar
Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J et al. (1985). Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science230: 1132–1139. ArticleCASPubMed Google Scholar
Engelman JA, Jänne PA, Mermel C, Pearlberg J, Mukohara T, Fleet C et al. (2005). ErbB-3 mediates PI3K activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci USA102: 3788–3793. ArticleCASPubMedPubMed Central Google Scholar
Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO et al. (2007). MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science316: 1039–1043. ArticleCASPubMed Google Scholar
Eskens FA, Mom CH, Planting AS, Gietema JA, Amelsberg A, Huisman H et al. (2008). A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br J Cancer98: 80–85. ArticleCASPubMed Google Scholar
Fan Z, Baselga J, Masui H, Mendelsohn J . (1993). Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res53: 4637–4642. CASPubMed Google Scholar
Greulich H, Chen TH, Feng W, Janne PA, Alvarez JV, Zappaterra M et al. (2005). Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med2: e313. ArticlePubMedPubMed Central Google Scholar
Hurwitz E, Klapper LN, Wilchek M, Yarden Y, Sela M . (2000). Inhibition of tumor growth by poly(ethylene glycol) derivatives of anti-ErbB2 antibodies. Cancer Immunol Immunother49: 226–234. ArticleCASPubMed Google Scholar
Hynes NE, Lane HA . (2005). ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer5: 341–354. ArticleCASPubMed Google Scholar
Janne PA, Engelman JA, Johnson BE . (2005). Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol23: 3227–3234. ArticleCASPubMed Google Scholar
Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C et al. (2006). Cancer statistics, 2006. CA Cancer J Clin56: 106–130. ArticlePubMed Google Scholar
Ji H, Li D, Chen L, Shimamura T, Kobayashi S, McNamara K et al. (2006a). The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell9: 485–495. ArticleCASPubMed Google Scholar
Ji H, Zhao X, Yuza Y, Shimamura T, Li D, Protopopov A et al. (2006b). Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc Natl Acad Sci USA103: 7817–7822. ArticleCASPubMedPubMed Central Google Scholar
Jiang J, Greulich H, Janne PA, Sellers WR, Meyerson M, Griffin JD . (2005). Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. Cancer Res65: 8968–8974. ArticleCASPubMed Google Scholar
Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M et al. (2005a). EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med352: 786–792. ArticleCASPubMed Google Scholar
Kobayashi S, Ji H, Yuza Y, Meyerson M, Wong KK, Tenen DG et al. (2005b). An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res65: 7096–7101. ArticleCASPubMed Google Scholar
Krypuy M, Newnham GM, Thomas DM, Conron M, Dobrovic A . (2006). High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. BMC Cancer6: 295. ArticlePubMedPubMed Central Google Scholar
Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW et al. (2005). Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA102: 7665–7670. ArticleCASPubMedPubMed Central Google Scholar
Lee JC, Vivanco I, Beroukhim R, Huang JH, Feng WL, Debiasi RM et al. (2006). Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med3: e485. ArticlePubMedPubMed Central Google Scholar
Li D, Ji H, Zaghlul S, McNamara K, Liang MC, Shimamura T et al. (2007a). Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent lung carcinomas. J Clin Invest117: 346–352. ArticleCASPubMedPubMed Central Google Scholar
Li D, Shimamura T, Ji H, Chen L, Haringsma HJ, McNamara K et al. (2007b). Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell12: 81–93. ArticleCASPubMed Google Scholar
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med350: 2129–2139. ArticleCASPubMed Google Scholar
Mulloy R, Ferrand A, Kim Y, Sordella R, Bell DW, Haber DA et al. (2007). Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib. Cancer Res67: 2325–2330. ArticleCASPubMed Google Scholar
Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S et al. (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science304: 1497–1500. ArticleCASPubMed Google Scholar
Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I et al. (2004). EGF receptor gene mutations are common in lung cancers from ‘never smokers’ and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA101: 13306–13311. ArticleCASPubMedPubMed Central Google Scholar
Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF et al. (2005a). Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib Is associated with a second mutation in the EGFR kinase domain. PLoS Med2: e73. ArticlePubMedPubMed Central Google Scholar
Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M et al. (2005b). KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med2: e17. ArticlePubMedPubMed Central Google Scholar
Rabindran SK, Discafani CM, Rosfjord EC, Baxter M, Floyd MB, Golas J et al. (2004). Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res64: 3958–3965. ArticleCASPubMed Google Scholar
Riely GJ, Pao W, Pham D, Li AR, Rizvi N, Venkatraman ES et al. (2006). Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res12: 839–844. ArticleCASPubMed Google Scholar
Schiffer HH, Reding EC, Fuhs SR, Lu Q, Piu F, Wong S et al. (2007). Pharmacology and signaling properties of epidermal growth factor receptor isoforms studied by bioluminescence resonance energy transfer. Mol Pharmacol71: 508–518. ArticleCASPubMed Google Scholar
Shigematsu H, Takahashi T, Nomura M, Majmudar K, Suzuki M, Lee H et al. (2005). Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res65: 1642–1646. ArticleCASPubMed Google Scholar
Shimamura T, Ji H, Minami Y, Thomas RK, Lowell AM, Shah K et al. (2006). Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272. Cancer Res66: 6487–6491. ArticleCASPubMed Google Scholar
Stephens P, Hunter C, Bignell G, Edkins S, Davies H, Teague J et al. (2004). Lung cancer: intragenic ERBB2 kinase mutations in tumors. Nature431: 525–526. ArticleCASPubMed Google Scholar
Ullrich A, Coussens L, Hayflick JS, Dull TJ, Gray A, Tam AW et al. (1984). Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature309: 418–425. ArticleCASPubMed Google Scholar
Vikis H, Sato M, James M, Wang D, Wang Y, Wang M et al. (2007). EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity. Cancer Res67: 4665–4670. ArticleCASPubMedPubMed Central Google Scholar
Wang SE, Narasanna A, Perez-Torres M, Xiang B, Wu FY, Yang S et al. (2006). HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell10: 25–38. ArticlePubMed Google Scholar
Yuza Y, Glatt KA, Jiang J, Greulich H, Minami Y, Woo MS et al. (2007). Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors. Cancer Biol Ther6: 661–667. ArticleCASPubMed Google Scholar